BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/25/2023 11:20:42 AM | Browse: 163 | Download: 571
 |
Received |
|
2023-06-22 05:21 |
|
Peer-Review Started |
|
2023-06-22 05:24 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-08 03:53 |
|
Revised |
|
2023-08-22 03:58 |
|
Second Decision |
|
2023-09-04 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-09-04 08:37 |
|
Articles in Press |
|
2023-09-04 08:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-13 09:15 |
|
Publish the Manuscript Online |
|
2023-09-25 11:20 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Yu Yang, Yu-Xuan Du, Yu-Jia Hou, Dian-Rong Lu and Peng Xue |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation |
No. 81973640 |
|
| Corresponding Author |
Dian-Rong Lu, Doctor, PhD, Chief Physician, Professor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100000, China. ludianrong@aliyun.com |
| Key Words |
Bladder urothelial carcinoma; Hyperprogression; Immunotherapy; Toripalimab; Case report |
| Core Tip |
We report a patient with bladder urothelial carcinoma (UC) who received anti- programmed death-ligand 1 agent toripalimab after surgery and chemotherapy over 12 mo had a treatment failure time less than 2 mo and showed a hyperprogression. Currently, it is still a challenge to select the patients most likely to respond to treatment with immunotherapeutic agents. For elderly patients with advanced UC, immunotherapy should be used prudently if there is no clear effective biomarker. In this case presentation, we include information on genetic alterations. With continued clinical trials and basic research, the risk factors for immunotherapy-related hyperprogressive disease will become clearer. |
| Publish Date |
2023-09-25 11:20 |
| Citation |
Yang HY, Du YX, Hou YJ, Lu DR, Xue P. Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report. World J Clin Cases 2023; 11(28): 6841-6849 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i28/6841.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i28.6841 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
